Bio-Rad Laboratories Statistics
Total Valuation
BIO.B has a market cap or net worth of $7.79 billion. The enterprise value is $7.83 billion.
| Market Cap | 7.79B |
| Enterprise Value | 7.83B |
Important Dates
The last earnings date was Thursday, July 31, 2025, after market close.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO.B has 5.07 million shares outstanding. The number of shares has decreased by -3.21% in one year.
| Current Share Class | 5.07M |
| Shares Outstanding | 5.07M |
| Shares Change (YoY) | -3.21% |
| Shares Change (QoQ) | -2.60% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 18.51M |
Valuation Ratios
The trailing PE ratio is 24.41 and the forward PE ratio is 28.76.
| PE Ratio | 24.41 |
| Forward PE | 28.76 |
| PS Ratio | 3.05 |
| Forward PS | 2.92 |
| PB Ratio | 1.09 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | 21.00 |
| P/OCF Ratio | 14.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.07, with an EV/FCF ratio of 21.09.
| EV / Earnings | 24.51 |
| EV / Sales | 3.06 |
| EV / EBITDA | 19.07 |
| EV / EBIT | 30.87 |
| EV / FCF | 21.09 |
Financial Position
The company has a current ratio of 5.12, with a Debt / Equity ratio of 0.20.
| Current Ratio | 5.12 |
| Quick Ratio | 3.37 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 2.94 |
| Debt / FCF | 3.79 |
| Interest Coverage | 5.17 |
Financial Efficiency
Return on equity (ROE) is 4.59% and return on invested capital (ROIC) is 1.90%.
| Return on Equity (ROE) | 4.59% |
| Return on Assets (ROA) | 1.59% |
| Return on Invested Capital (ROIC) | 1.90% |
| Return on Capital Employed (ROCE) | 2.62% |
| Revenue Per Employee | $331,714 |
| Profits Per Employee | $41,455 |
| Employee Count | 7,700 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 1.50 |
Taxes
In the past 12 months, BIO.B has paid $130.90 million in taxes.
| Income Tax | 130.90M |
| Effective Tax Rate | 29.08% |
Stock Price Statistics
The stock price has decreased by -9.42% in the last 52 weeks. The beta is 0.94, so BIO.B's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | -9.42% |
| 50-Day Moving Average | 249.79 |
| 200-Day Moving Average | 281.65 |
| Relative Strength Index (RSI) | 30.42 |
| Average Volume (20 Days) | 42 |
Short Selling Information
The latest short interest is 102, so 0.00% of the outstanding shares have been sold short.
| Short Interest | 102 |
| Short Previous Month | 40 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 20.40 |
Income Statement
In the last 12 months, BIO.B had revenue of $2.55 billion and earned $319.20 million in profits. Earnings per share was $11.49.
| Revenue | 2.55B |
| Gross Profit | 1.35B |
| Operating Income | 253.50M |
| Pretax Income | n/a |
| Net Income | 319.20M |
| EBITDA | 410.30M |
| EBIT | 253.50M |
| Earnings Per Share (EPS) | $11.49 |
Balance Sheet
The company has $1.37 billion in cash and $1.41 billion in debt, giving a net cash position of -$32.70 million or -$6.45 per share.
| Cash & Cash Equivalents | 1.37B |
| Total Debt | 1.41B |
| Net Cash | -32.70M |
| Net Cash Per Share | -$6.45 |
| Equity (Book Value) | 7.13B |
| Book Value Per Share | 263.42 |
| Working Capital | 2.26B |
Cash Flow
In the last 12 months, operating cash flow was $534.20 million and capital expenditures -$163.20 million, giving a free cash flow of $371.00 million.
| Operating Cash Flow | 534.20M |
| Capital Expenditures | -163.20M |
| Free Cash Flow | 371.00M |
| FCF Per Share | $73.17 |
Margins
Gross margin is 52.96%, with operating and profit margins of 9.92% and 12.50%.
| Gross Margin | 52.96% |
| Operating Margin | 9.92% |
| Pretax Margin | 17.62% |
| Profit Margin | 12.50% |
| EBITDA Margin | 16.06% |
| EBIT Margin | 9.92% |
| FCF Margin | 14.53% |
Dividends & Yields
BIO.B does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.21% |
| Shareholder Yield | 3.21% |
| Earnings Yield | 4.10% |
| FCF Yield | 4.76% |
Analyst Forecast
The average price target for BIO.B is $333.50, which is 12.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $333.50 |
| Price Target Difference | 12.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 1.78% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO.B has an Altman Z-Score of 3.31 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.31 |
| Piotroski F-Score | 5 |